Bright Minds Net Income Over Time
| DRUG Stock | USD 75.97 2.89 3.95% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Bright Minds Performance and Bright Minds Correlation. Can Biotechnology industry sustain growth momentum? Does Bright have expansion opportunities? Factors like these will boost the valuation of Bright Minds. Projected growth potential of Bright fundamentally drives upward valuation adjustments. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Bright Minds demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Bright Minds Biosciences's market price often diverges from its book value, the accounting figure shown on Bright's balance sheet. Smart investors calculate Bright Minds' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Since Bright Minds' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Bright Minds' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Bright Minds should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Bright Minds' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Income Analysis
Compare Bright Minds Biosciences and related stocks such as LB Pharmaceuticals Common, Design Therapeutics, and Aura Biosciences Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LBRX | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (6.3 M) | (63.1 M) | (56.8 M) | (54 M) |
| DSGN | (2 M) | (2 M) | (2 M) | (2 M) | (2 M) | (2 M) | (2 M) | (2 M) | (2 M) | (2 M) | (8.3 M) | (35.5 M) | (58.6 M) | (66.9 M) | (49.6 M) | (44.6 M) | (46.9 M) |
| AURA | (24.2 M) | (24.2 M) | (24.2 M) | (24.2 M) | (24.2 M) | (24.2 M) | (24.2 M) | (24.2 M) | (24.2 M) | (24.2 M) | (22.2 M) | (35.3 M) | (58.8 M) | (76.4 M) | (86.9 M) | (78.2 M) | (82.1 M) |
| DMAC | (640 K) | (6.6 M) | (10.1 M) | (7.4 M) | (4.8 M) | (1.4 M) | (2.2 M) | (4.3 M) | (5.7 M) | (10.6 M) | (12.3 M) | (13.6 M) | (13.7 M) | (19.4 M) | (24.4 M) | (22 M) | (20.9 M) |
| ALT | 277.3 K | (3.8 M) | (4.9 M) | (11.7 M) | (10 M) | (3.4 M) | 193.9 M | (46.4 M) | (39.2 M) | (20.5 M) | (49 M) | (97.1 M) | (84.7 M) | (88.4 M) | (95.1 M) | (85.6 M) | (81.3 M) |
| ANNX | (18.7 M) | (18.7 M) | (18.7 M) | (18.7 M) | (18.7 M) | (18.7 M) | (18.7 M) | (18.7 M) | (18.3 M) | (37.2 M) | (62.7 M) | (127.8 M) | (138.3 M) | (134.2 M) | (138.2 M) | (124.4 M) | (130.6 M) |
| GALT | (190 K) | (10.9 M) | (9.7 M) | (12.1 M) | (15.8 M) | (20 M) | (21.4 M) | (16.2 M) | (13.9 M) | (13.3 M) | (23.5 M) | (30.5 M) | (38.8 M) | (41.1 M) | (47 M) | (42.3 M) | (40.2 M) |
| KRRO | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (19.2 M) | (18.7 M) | (26.5 M) | (84.7 M) | (58 M) | (81.2 M) | (83.6 M) | (75.2 M) | (79 M) |
Bright Minds Biosciences and related stocks such as LB Pharmaceuticals Common, Design Therapeutics, and Aura Biosciences Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Bright Minds Biosciences financial statement analysis. It represents the amount of money remaining after all of Bright Minds Biosciences operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Bright Minds Biosciences | DRUG |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 19 Vestry Street, |
| Exchange | NASDAQ Exchange |
USD 75.97
Check out Bright Minds Performance and Bright Minds Correlation. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Bright Minds technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.